Home
Products

Recombinant Proteins
Bioactive Proteins Cytokines and Growth Factors Immune Checkpoint Proteins Enzyme Other Proteins

Antibodies
Primary antibodies Recombinant Monoclonal Antibodies Secondary antibodies Flow Cytometry (FACS) Antibodies Neutralizing Antibodies Isotype Controls Research Grade Biosimilars InVivo Plus InVivo Antibodies XtenNano®Nanobodies Bispecific Antibodies Antibodies against Small Molecules Tag Antibodies Anti-idiotype Antibodies

Assay Kits
ELISA Kits ADA Assay Kits PK Assay Kits Antibody Pairs
Research Area
Featured Products
Support
Information
- BioSpotlight
- Literature Highlights
About Us
Promotion Center

Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial (related clinical context)

Nature Medicine

An interim analysis of a phase 3 randomized trial involving adults with IgA nephropathy showed that ravulizumab, a terminal complement inhibitor, led to a significantly greater reduction in proteinuria than placebo.

Related products

Catalog No.	Product Name	Description	Target
HF687016	Anti-Human Complement C5 Reference Antibody (Ravulizumab	Ravulizumab (HF687016) is a research-grade recombinant antibody targeting CPAMD4. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.	CPAMD4, C5, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, Complement C5

Recombinant Proteins

Antibodies

Assay Kits

Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial (related clinical context)